These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 25871383)
1. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. Lonetti A; Cappellini A; Spartà AM; Chiarini F; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; McCubrey JA; Martelli AM Oncotarget; 2015 Apr; 6(12):10399-414. PubMed ID: 25871383 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846 [TBL] [Abstract][Full Text] [Related]
3. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia. Pereira JK; Machado-Neto JA; Lopes MR; Morini BC; Traina F; Costa FF; Saad ST; Favaro P Eur J Cancer; 2015 Sep; 51(14):2076-85. PubMed ID: 26238016 [TBL] [Abstract][Full Text] [Related]
4. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement. Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877 [TBL] [Abstract][Full Text] [Related]
6. Andrographolide inhibits growth of human T-cell acute lymphoblastic leukemia Jurkat cells by downregulation of PI3K/AKT and upregulation of p38 MAPK pathways. Yang T; Yao S; Zhang X; Guo Y Drug Des Devel Ther; 2016; 10():1389-97. PubMed ID: 27114702 [TBL] [Abstract][Full Text] [Related]
7. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803 [TBL] [Abstract][Full Text] [Related]
8. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Hall CP; Reynolds CP; Kang MH Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839 [TBL] [Abstract][Full Text] [Related]
9. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). Gazi M; Moharram SA; Marhäll A; Kazi JU Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681 [TBL] [Abstract][Full Text] [Related]
10. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Hales EC; Taub JW; Matherly LH Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475 [TBL] [Abstract][Full Text] [Related]
11. Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. Lynch JT; McEwen R; Crafter C; McDermott U; Garnett MJ; Barry ST; Davies BR Oncotarget; 2016 Apr; 7(16):22128-39. PubMed ID: 26989080 [TBL] [Abstract][Full Text] [Related]
12. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. Gusscott S; Jenkins CE; Lam SH; Giambra V; Pollak M; Weng AP PLoS One; 2016; 11(8):e0161158. PubMed ID: 27532210 [TBL] [Abstract][Full Text] [Related]
13. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Evangelisti C; Ricci F; Tazzari P; Tabellini G; Battistelli M; Falcieri E; Chiarini F; Bortul R; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Martelli AM Leukemia; 2011 May; 25(5):781-91. PubMed ID: 21331075 [TBL] [Abstract][Full Text] [Related]
14. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642 [TBL] [Abstract][Full Text] [Related]
15. PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia. Silveira AB; Laranjeira AB; Rodrigues GO; Leal PC; Cardoso BA; Barata JT; Yunes RA; Zanchin NI; Brandalise SR; Yunes JA Oncotarget; 2015 May; 6(15):13105-18. PubMed ID: 25869207 [TBL] [Abstract][Full Text] [Related]
16. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. Evangelisti C; Ricci F; Tazzari P; Chiarini F; Battistelli M; Falcieri E; Ognibene A; Pagliaro P; Cocco L; McCubrey JA; Martelli AM J Cell Physiol; 2011 Mar; 226(3):822-31. PubMed ID: 20857426 [TBL] [Abstract][Full Text] [Related]
17. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816 [TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. Young CD; Arteaga CL; Cook RS Breast Cancer Res; 2015 Dec; 17():148. PubMed ID: 26637440 [TBL] [Abstract][Full Text] [Related]
19. Targeting nonclassical oncogenes for therapy in T-ALL. Subramaniam PS; Whye DW; Efimenko E; Chen J; Tosello V; De Keersmaecker K; Kashishian A; Thompson MA; Castillo M; Cordon-Cardo C; Davé UP; Ferrando A; Lannutti BJ; Diacovo TG Cancer Cell; 2012 Apr; 21(4):459-72. PubMed ID: 22516257 [TBL] [Abstract][Full Text] [Related]
20. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]